the aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe ulcerative colitis (uc) in iran. we developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. hypothetical patients, were individuals with moderate to sev...

background: the present study aims to evaluate the cost-effectiveness of dynamic interspinous spacer (coflex®) and static spacer (x-stop ®) compared to laminectomy (lami) in patients with lumbar spinal stenosis.   methods: a decision-analysis model was developed to estimate the cost-effectiveness. the effectiveness parameters were obtained from a systematic literature review in relevant databas...

objectives the aim of this study was to study the incremental cost-effectiveness ratio associated with the use of heat and moisture exchangers (hme) filter to prevent vap compared with the heated humidifiers (hh) presently adopted by intensive care unit (icu) services within the brazilian healthcare unified system. patients and methods this study was a cost-effectiveness analysis (cea) comparin...

background: the rabies is one of the most important officially-known viral zoonotic diseases for its global distribution, outbreak, high human and veterinary costs, and high death rate and causes high economic costs in different countries of the world every year. the rabies is the deadliest disease and if the symptoms break out in a person, one will certainly die. however, the deaths resulting ...

Background: The present study aims to evaluate the cost-effectiveness of Dynamic Interspinous Spacer (Coflex®) and Static Spacer (X-STOP ®) compared to Laminectomy (LAMI) in patients with lumbar spinal stenosis.   Methods: A decision-analysis model was developed to estimate the cost-effectiveness. The effectiveness parameters were obtained from a systematic literature review in ...

BACKGROUND The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utili...

BACKGROUND The NCIC Clinical Trials Group conducted the BR.21 trial, a randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor) in patients with previously treated advanced non-small cell lung cancer. This trial accrued patients between August 14, 2001, and January 31, 2003, and found that overall survival and quality of life were improved...